Isatuximab previously lagged its competitor, daratumumab, which had a subcutaneous option for years. The new on-body injector (OBI) isn't just about catching up; its efficiency and high patient preference could shift treatment patterns, making it a significant competitive threat and altering its market position.
Quantitative data from the ISOLICAL trial reveals an overwhelming patient preference for on-body injectors (OBI) over manual injection. With 75% preferring OBI and 90% choosing it when given an option, patient experience—driven by comfort, reduced pain, and convenience—emerges as a critical factor for technology adoption in oncology.
The isatuximab on-body injector (OBI) is more than an in-clinic convenience; it represents a key technological step toward moving oncology treatment out of specialized centers. This could enable care closer to or even at patients' homes, particularly benefiting rural patients who face significant travel burdens.